Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Glox Therapeutics, a company pioneering the development of precision antibiotics to combat antimicrobial resistance, has raised £4.3M in early-stage funding to develop effective targeted therapeutics against antibiotic-resistant gram-negative bacteria.

antibiotics © Shutterstock

Antimicrobial resistance (AMR) is a major public health crisis throughout the world. It is estimated that around 1.27 million people per year die as a result of AMR due to the therapeutic failure of available antibiotics.

By 2050, AMR is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion, and there is an urgent need to develop new effective antimicrobial therapeutics.

Glox Therapeutics is developing precision antibiotics by using engineered protein bacteriocins. These novel antimicrobials exhibit remarkable potency and specificity, enabling them to effectively and selectively target gram-negative pathogens that have already developed AMR.#

Read the full story on the University of Oxford website.

Similar stories

Novel inhaled TB vaccine

The Jenner Institute is conducting a new study, using BCG, the current licensed vaccine against tuberculosis. In this study, they will give BCG a second time to people who have already had BCG once before, and will compare whether giving it by inhalation is better at protecting people against tuberculosis than giving it into the skin